Peptide · Fact sheet

Pramlintide

Also known as Symlin · pramlintide acetate

Symlin received FDA approval for selected insulin-treated diabetes populations, but FDA lists its U.S. presentations as discontinued. Pramlintide is not approved as a stand-alone obesity medicine.

DiscontinuedStrong human evidence for approved uses

What is Pramlintide?

Pramlintide is a manufactured analog of amylin, a peptide hormone normally released with insulin after eating.

Amylin signaling affects stomach emptying, glucagon release, satiety, and blood glucose, which also made the pathway important in obesity-drug research.

Benefits & claims

It is the established clinical proof that amylin biology can be used therapeutically.

Weight changes in diabetes and older obesity trials helped motivate longer-acting amylin analogs such as cagrilintide, but the molecules and evidence are not interchangeable.

What the evidence supports

  • Controlled diabetes trials showed improved glycemic outcomes when pramlintide was added in the labeled setting.
  • Older obesity trials found weight-loss signals, but pramlintide did not become a stand-alone FDA-approved obesity medicine.
Research areas
  • Glucose control with mealtime insulin
  • Satiety and food intake
  • Obesity and weight outcomes
  • Obesity treatment outside the approved diabetes context
  • Amylin-based combination medicines

Dosage & frequency

Historical product label information

The historical Symlin label describes separate mealtime regimens for type 1 and type 2 diabetes. FDA product records list the branded products as discontinued.

Symlin: type 1 diabetes: historical label

Adults with type 1 diabetes using mealtime insulin

Amount
Start 15 mcg; labeled increments 30, 45 and 60 mcg as tolerated
Frequency
Immediately before major meals
Route studied or labeled
Subcutaneous

Requires prescriber-directed mealtime insulin adjustment and glucose monitoring. Historical labeling; branded FDA product records are discontinued.

Symlin: type 2 diabetes: historical label

Adults with type 2 diabetes using mealtime insulin

Amount
Start 60 mcg; increase to 120 mcg as tolerated
Frequency
Immediately before major meals
Route studied or labeled
Subcutaneous

Severe hypoglycemia risk; not standalone treatment. Historical labeling; branded FDA product records are discontinued.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Pramlintide and the investigational long-acting amylin analog cagrilintide have different schedules.

Interactions & precautions

  • Concurrent mealtime insulin creates severe hypoglycemia risk and requires prescriber-directed insulin adjustment; oral drug absorption can also be delayed.

What is still unresolved

  • The approved regimen does not establish standalone obesity treatment.

Side effects & risks

  • The label carries a boxed warning for severe hypoglycemia when used with mealtime insulin, especially in type 1 diabetes.
  • Nausea and other gastrointestinal effects are common.
  • Its approved use requires clinical management that cannot be generalized to consumer weight-loss use.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Randomized trials support the scoped diabetes indication. Obesity research without insulin-treated diabetes is older and does not create a current stand-alone weight-management approval.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Feeling fuller, harder insulin management

A commenter who had used Symlin described substantially better fullness, while finding insulin management more difficult.

Amount, frequency, route and duration could not be confirmed for this account.

The summary concerns the author's own experience only, not their claims about other users. Glucose outcomes and insulin exposure were not verified.

Read the original account
Mixed account · personal report

Less appetite but severe nausea

A different commenter described recurring nausea and reduced appetite, with post-meal glucose rises seeming delayed rather than eliminated.

Amount, frequency, route and duration could not be confirmed for this account.

This does not establish a glucose-control mechanism or quantify risk. Concurrent insulin and clinical records were not available.

Read the original account
Mixed account · personal report

Early weight loss, diminishing practical benefit

Another commenter reported less appetite, weight loss and lower insulin requirements over several weeks, but later felt the benefit was less worthwhile.

Reported use in this account

Product
Symlin
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Injection; specific route not stated
Duration
A few months

Other exposures described: Insulin

The account's explanation of tolerance was not clinically confirmed, and weight and insulin changes were self-reported.

Read the original account

Approval status

FDA lists the U.S. Symlin presentations as discontinued. Its historical approval covered selected adults with type 1 or type 2 diabetes using mealtime insulin. Marketing discontinuation does not by itself establish an approval withdrawal or its reason.

U.S. Symlin products discontinued

Symlin received a product-specific diabetes approval. FDA now lists its U.S. presentations as discontinued; that marketing status does not by itself establish an approval withdrawal or the reason for discontinuation. Its obesity research did not create a stand-alone weight-loss approval.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether pramlintide has a useful modern obesity role compared with other agents
  • Long-term outcomes for unapproved weight-management use
  • How benefits and harms compare with longer-acting amylin analogs
  • Which combination strategies, if any, will prove clinically superior

Summary

Symlin has a historical diabetes approval and discontinued U.S. marketing status. Its label and trials do not establish a stand-alone weight-loss approval.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA Drugs@FDA dataset: Symlin product status

    All three listed Symlin products have discontinued marketing status; this does not establish approval withdrawal.

  2. fdaFDA prescribing information: Symlin

    Approved population, boxed warning, adverse reactions, and clinical evidence.

  3. pubmedOne-year randomized pramlintide diabetes trial

    Controlled evidence for glycemic and weight outcomes in insulin-treated type 2 diabetes.

  4. pubmedRandomized pramlintide obesity study

    Older exploratory obesity study that does not establish an approved stand-alone use.

How we assess sources · Suggest a correction